Novo Nordisk Eli Lilly

Novo Nordisk, food and drug administration and Shortage

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.

Wall Street Journal · 18h

Novo Nordisk Shares Rise After FDA Clears Shortage of Anti-Obesity Drugs

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o

Business Insider · 18h

Shortage of Novo Nordisk’s (NVO) Weight Loss Drugs Is Resolved, Says FDA

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration

CBS News on MSN · 20h

FDA declares end to Wegovy and Ozempic shortage

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

USA TODAY on MSN · 19h

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions

Business Insider · 22h

Novo Nordisk up 6%, Hims & Hers down 15% as FDA says Ozempic shortage over

Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of

Eli Lilly, Weight Loss Pill

Hosted on MSN · 1d

Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements,

Business Insider · 1d

Eli Lilly (LLY) Stockpiles Weight Loss Pill Ahead of Regulatory Approval

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the

Quartz on MSN · 1d

Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss meds into tackling some of the world’s toughest health challenges.

20hon MSN

Why Novo Nordisk Stock Popped on Friday

Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli ...

FiercePharma21h

Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Why Novo Nordisk Is A Strong Buy Despite Market Concerns

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

16d

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

BioSpace10d

Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

25d

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...

13d

Novo Nordisk: 2024 Earnings Review

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results